FOXO TECHNOLOGIES Business Summary

FOXO Technologies Inc. (FOXO) operates as a diversified healthcare services and biotechnology company, generating revenue through a hybrid model of clinical service fees, life insurance commissions, and technology licensing. The company is organized into two primary business segments: Healthcare and Labs. The Healthcare segment manages critical access hospitals and behavioral health facilities, such as the Big South Fork Medical Center and Myrtle Recovery Centers, providing inpatient, outpatient, and detoxification services. The Labs segment commercializes proprietary epigenetic biomarker technology, utilizing AI and DNA methylation data to provide longevity-based risk assessments for the life insurance industry and bioinformatics services for pharmaceutical research. FOXO competes directly with epigenetic platforms like Chroma Medicine, Chronomics, and Moonwalk, positioning itself as a micro-cap consolidator that bridges clinical healthcare delivery with advanced molecular diagnostics. Leadership is currently spearheaded by CEO Seamus Lagan, an entrepreneur with over 30 years of experience in distressed asset management and healthcare M&A, who also serves as the CEO of Rennova Health, Inc. The executive team includes CFO Sylwia Nowak Hauman, who was appointed in late 2025 to oversee the company’s financial restructuring following its transition to the OTC market. The company’s strategic direction is heavily influenced by its majority shareholder, Rennova Health, Inc., which holds a controlling interest. The Board of Directors features independent members such as Mark White, who previously served as Interim CEO, and Bret Barnes, providing oversight as the firm executes a pivot toward rural healthcare stabilization and direct-to-consumer longevity reporting.